1440 related articles for article (PubMed ID: 17956348)
21. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
22. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
24. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T; Ashihara E; Kimura S
Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
[TBL] [Abstract][Full Text] [Related]
25. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
26. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L; Talpaz M
Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
[TBL] [Abstract][Full Text] [Related]
29. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
30. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
DeAngelo DJ; Attar EC
Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
[TBL] [Abstract][Full Text] [Related]
31. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
32. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
[TBL] [Abstract][Full Text] [Related]
33. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
34. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib: is it all in the dose?
Condorelli F; Genazzani AA
BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
[TBL] [Abstract][Full Text] [Related]
37. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
38. ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Wang Z; Liu Z; Wu X; Chu S; Wang J; Yuan H; Roth M; Yuan YC; Bhatia R; Chen W
PLoS Genet; 2014 Jun; 10(6):e1004414. PubMed ID: 24967705
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
40. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
